Peden N R, Dow R J, Isles T E, Martin B T
Br Med J (Clin Res Ed). 1984 Jun 16;288(6433):1788-90. doi: 10.1136/bmj.288.6433.1788.
During a randomised placebo controlled trial of the effects of nadolol in hypertensive patients serum lipid profiles were obtained while the patients were fasting and during and after a meal and an exercise test. Treatment with nadolol was associated with a significant reduction in high density lipoprotein cholesterol at all time points. Serum triglyceride concentrations during treatment with nadolol were higher in the fasting state, though not significantly so, increased further postprandially, and were significantly higher during and after exercise. The changes in high density lipoprotein cholesterol and triglyceride concentrations during beta adrenoceptor blockade may be secondary to a reduction in lipoprotein lipase activity.
在一项关于纳多洛尔对高血压患者影响的随机安慰剂对照试验中,在患者空腹时、进餐期间及进餐后以及运动试验期间和之后获取了血脂谱。在所有时间点,使用纳多洛尔治疗均与高密度脂蛋白胆固醇显著降低相关。纳多洛尔治疗期间,空腹状态下血清甘油三酯浓度较高,虽无显著差异,但餐后进一步升高,且在运动期间和运动后显著更高。β肾上腺素能受体阻断期间高密度脂蛋白胆固醇和甘油三酯浓度的变化可能继发于脂蛋白脂肪酶活性降低。